In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.
Karen E. Knudsen, PhD
Advertisement
Articles by Karen E. Knudsen, PhD
Advertisement
Latest Updated Articles
COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only?December 17th 2018
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCO Releases New Patient-Clinician Communication Guidelines
2
NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype
3
Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial
4
Melanoma Vaccine Receives FDA Fast Track Designation
5